Don Hayes1,2,3,4, Dmitry Tumin5,6, Joseph D Tobias7,6. 1. Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA. hayes.705@osu.edu. 2. Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH, USA. hayes.705@osu.edu. 3. Section of Pulmonary Medicine, Nationwide Children's Hospital, Columbus, OH, USA. hayes.705@osu.edu. 4. The Ohio State University, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH, 43205, USA. hayes.705@osu.edu. 5. Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA. 6. Department of Anesthesiology & Pain Medicine, Nationwide Children's Hospital, Columbus, OH, USA. 7. Department of Anesthesiology, The Ohio State University College of Medicine, Columbus, OH, USA.
Abstract
BACKGROUND: Survival implications of pre-transplant antibodies to human leukocyte antigens prior to lung transplantation (LTx) in adult cystic fibrosis (CF) patients are unknown. METHODS: Data from the United Network for Organ Sharing Registry (1987-2013) were used to compare survival differences in adult CF patients with pre-transplant class I and II panel reactive antibody (PRA) levels ≤10 versus >10 %. RESULTS: Of 3149 CF LTx recipients, 1526 and 1399 were included in univariate survival analyses of class I and II PRA, respectively, while 1106 and 1001 were included in multivariate Cox analyses for class I and class II, respectively. Kaplan-Meier survival functions failed to demonstrate significant differences in survival with PRA >10 % for class I (Log-rank test: χ (2) (df = 1): 1.11, p = 0.293) or class II (Log-rank test: χ (2) (df = 1): 0.99, p = 0.320). Adjusting for covariates, multivariate Cox models demonstrated that class II PRA >10 % was associated with a significant increase in mortality hazard (HR 1.918; 95 % CI 1.128, 3.261; p = 0.016), whereas class I PRA >10 % was uncorrelated with this outcome. CONCLUSIONS: Pre-transplant PRA class II >10 % in adult CF patients is associated with elevated mortality hazard after LTx.
BACKGROUND: Survival implications of pre-transplant antibodies to human leukocyte antigens prior to lung transplantation (LTx) in adult cystic fibrosis (CF) patients are unknown. METHODS: Data from the United Network for Organ Sharing Registry (1987-2013) were used to compare survival differences in adult CFpatients with pre-transplant class I and II panel reactive antibody (PRA) levels ≤10 versus >10 %. RESULTS: Of 3149 CFLTx recipients, 1526 and 1399 were included in univariate survival analyses of class I and II PRA, respectively, while 1106 and 1001 were included in multivariate Cox analyses for class I and class II, respectively. Kaplan-Meier survival functions failed to demonstrate significant differences in survival with PRA >10 % for class I (Log-rank test: χ (2) (df = 1): 1.11, p = 0.293) or class II (Log-rank test: χ (2) (df = 1): 0.99, p = 0.320). Adjusting for covariates, multivariate Cox models demonstrated that class II PRA >10 % was associated with a significant increase in mortality hazard (HR 1.918; 95 % CI 1.128, 3.261; p = 0.016), whereas class I PRA >10 % was uncorrelated with this outcome. CONCLUSIONS: Pre-transplant PRA class II >10 % in adult CFpatients is associated with elevated mortality hazard after LTx.
Authors: Don Hayes; Sylvester M Black; Joseph D Tobias; Benjamin T Kopp; Stephen E Kirkby; Heidi M Mansour; Bryan A Whitson Journal: J Heart Lung Transplant Date: 2015-09-25 Impact factor: 10.247
Authors: S Sundaresan; T Mohanakumar; M A Smith; E P Trulock; J Lynch; D Phelan; J D Cooper; G A Patterson Journal: Transplantation Date: 1998-03-15 Impact factor: 4.939
Authors: M A Smith; S Sundaresan; T Mohanakumar; E P Trulock; J P Lynch; D L Phelan; J D Cooper; G A Patterson Journal: J Thorac Cardiovasc Surg Date: 1998-11 Impact factor: 5.209
Authors: Yaron D Barac; Mike S Mulvihill; Oliver Jawitz; Jacob Klapper; John Haney; Mani Daneshmand; Basil Nasir; Dongfeng Chen; Carmelo A Milano; Matthew G Hartwig Journal: Ann Thorac Surg Date: 2020-04-03 Impact factor: 4.330
Authors: Sung Woo Moon; Moo Suk Park; Jin Gu Lee; Hyo Chae Paik; Young Tae Kim; Hyun Joo Lee; Samina Park; Sun Mi Choi; Do Hyung Kim; Woo Hyun Cho; Hye Ju Yeo; Seung Il Park; Se Hoon Choi; Sang Bum Hong; Tae Sun Shim; Kyung Wook Jo; Kyeongman Jeon; Byeong Ho Jeong; Song Yee Kim Journal: Yonsei Med J Date: 2020-07 Impact factor: 2.759